Public Employees Retirement Association of Colorado’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-3,958
Closed -$149K 1941
2021
Q1
$149K Hold
3,958
﹤0.01% 1786
2020
Q4
$67K Sell
3,958
-3,044
-43% -$38.1K ﹤0.01% 1850
2020
Q3
$33K Hold
7,002
﹤0.01% 1856
2020
Q2
$43K Hold
7,002
﹤0.01% 1829
2020
Q1
$16K Hold
7,002
﹤0.01% 1790
2019
Q4
$32K Hold
7,002
﹤0.01% 1811
2019
Q3
$27K Hold
7,002
﹤0.01% 1839
2019
Q2
$42K Hold
7,002
﹤0.01% 1853
2019
Q1
$94K Hold
7,002
﹤0.01% 1729
2018
Q4
$65K Hold
7,002
﹤0.01% 1796
2018
Q3
$97K Buy
7,002
+4,507
+181% +$67K ﹤0.01% 1815
2018
Q2
$39K Hold
2,495
﹤0.01% 1865
2018
Q1
$43K Hold
2,495
﹤0.01% 1860
2017
Q4
$55K Buy
+2,495
New +$80.2K ﹤0.01% 1851

Public Employees Retirement Association of Colorado's FPRX Position: Q2 2021 in Review

Public Employees Retirement Association of Colorado sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 3,958 shares — an estimated $149K sold.

Public Employees Retirement Association of Colorado first reported a position in FPRX in Q4 2017 and held it in 14 quarters. The position peaked at $149K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Public Employees Retirement Association of Colorado reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Public Employees Retirement Association of Colorado sold 3,958 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $149K.
  • Public Employees Retirement Association of Colorado first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 14 quarters.
  • Public Employees Retirement Association of Colorado's Five Prime Therapeutics, Inc. position peaked at $149K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Public Employees Retirement Association of Colorado's 13F filing for Q2 2021, filed 13 Aug 2021.